Genmab A/S (GMAB) Social Stream



Genmab A/S (GMAB): $33.94

0.51 (+1.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GMAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Genmab A (GMAB) Price Targets From Analysts

Use the tables below to see what analysts covering Genmab A think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-11 6 $50 $37 $44.8 $36.03 24.34%
2021-11-15 7 $50 $37 $44.7 $36.03 24.06%
2022-01-18 8 $50 $37 $44.7 $36.03 24.06%
2022-01-31 8 $50 $37 $44.7 $36.03 24.06%
2022-02-28 8 $50 $37 $42.2 $36.03 17.12%
2022-03-04 8 $50 $33 $41.4 $36.03 14.9%

The Trend in the Analyst Price Target


GMAB's average price target has moved down $3.3 over the prior 113 days.

Over the past 143 days, GMAB's average upside potential has been 17.39%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-10-12 6 50 37 44.8 42.00 6.67%
2021-11-15 8 50 37 44.7 41.17 8.57%
2021-11-15 7 50 37 44.7 41.17 8.57%
2022-01-31 8 50 37 44.7 34.08 31.16%
2022-02-17 8 50 37 42.2 32.68 29.13%

GMAB Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.66 3 0 3 2 2 8

The Trend in the Broker Recommendations


Over the past 17 months, GMAB's average broker recommendation rating worsened by 0.54.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • Genmab A's upside potential (average analyst target price relative to current price) is higher than 57.42% of Pharmaceutical Products stocks.
  • In terms of how Genmab A fares relative to stocks in the large market cap category, note that its number of analysts covering the stock is higher than 103.99% of that group.
  • To contextualize these metrics, consider that out of stocks in the large market cap category, Genmab A's average analyst price target is greater than 134.9% of them.
  • In the context of Pharmaceutical Products stocks, Genmab A's variance in analysts' estimates is lower than -50.92% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Genmab A are GLPG, ENDP, and ELAN.

Is GMAB a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.574 seconds.